11:52 AM EST, 01/22/2025 (MT Newswires) -- Clearside Biomedical ( CLSD ) said Wednesday its China-based partner, Arctic Vision, has received regulatory approvals in Australia and Singapore for Arcatus, an injection therapy for the treatment of uveitic macular edema.

Arcatus is the brand name used for Clearside's Xipere medication outside the US.

Arctic Vision, which has the exclusive license for the commercialization and development Xipere in the Asia-Pacific region, has received approvals for its new drug applications for Arcatus from the Therapeutic Goods Administration of Australia and the Health Sciences Authority in Singapore, Clearside said.

Shares of Clearside were up about 2% in recent trading.

Price: 0.94, Change: +0.02, Percent Change: +1.92